MarginsXMarginsX
Home › Markets › Health Care › PTCT

PTC Therapeutics Inc. (PTCT)

PTCT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$60.97
-3.97% on the day
Market cap
$5.1B
Mid cap
Revenue · 2025
$1.7B
+114.5% on 2024
Net income · 2025
$682.6M
39.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1070081/000110465926017575/0001104659-26-017575-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerPTCT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2013
SEC CIK0001070081
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$1.7B
Net income$682.6M
Operating income$866.9M
Net margin39.4%
Operating margin50.1%
Revenue growth+114.5%
Cash$984.6M
Total assets$2.9B
P/E (computed)7.5×
P/S (computed)2.9×

Warning signs

Cash runway
Cash-flow positive
$508.9M cash at September 30, 2026
Share count, 1 year
+4.1%
2025-11-03 to 2026-10-27 · +10.7% over 3 years
Going-concern doubt
No
10-Q filed October 29, 2026
Insider net buying, 12 months
-$64.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-29
Cash and burn$508.9M cash; operating cash flow $2.6M a quarter.Report 2026-09-30
Shares outstanding83,544,284 (2026-10-27); 80,288,305 a year earlier; 75,463,145 three years earlier.Cover page 2026-10-27
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Iselin, New Jersey, United StatesPCAOB Form AP 2026-03-04
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $64.6M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$357.8M-$51.7M-$25.3M$508.9M$536.3M$1.2B10-Q 2026-10-29
Q2 2026
2026-06-30
$360.5M$83.5M$129.1M$1.0B$591.0M$1.0B10-Q 2026-07-30
Q1 2026
2026-03-31
$272.6M-$2.8M-$59.0M$834.0M$286.9M$827.1M10-Q 2026-05-07
Q4 2025
2025-12-31
$164.7M-$135.0M-$34.3M$984.6M$286.6M$1.7B10-K 2026-02-19
Q3 2025
2025-09-30
$211.0M$15.9M-$66.3M$672.6M$286.3M$1.8B10-Q 2026-10-29
Q2 2025
2025-06-30
$178.9M-$64.8M-$58.3M$1.0B$286.0M$1.8B10-Q 2026-07-30
Q1 2025
2025-03-31
$1.2B$866.6M$870.1M$1.5B$285.7M$1.8B10-Q 2026-05-07
Q4 2024
2024-12-31
$213.2M-$65.9M-$30.0M$779.7M$285.4M$806.8M10-K 2026-02-19

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2023-05-05
Latest annual report10-K2026-02-19
Latest quarterly / interim10-Q2026-10-29
Latest current report8-K2026-11-03
Latest proxyDEFA14A2026-04-20

Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-3.0%
1 month+6.0%
3 months-11.8%
Year to date-16.4%
1 year-15.3%
From 52-week high-29.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
LQDALiquidia Corporation$56.37-1.81%$5.1B
DNTHDianthus Therapeutics Inc.$89.55-2.46%$5.0B
ERASErasca Inc.$15.11-3.51%$5.3B
MANEVeradermics Incorporated$128.05-1.24%$5.4B
EWTXEdgewise Therapeutics Inc.$43.68-4.90%$4.8B
COGTCogent Biosciences Inc.$27.44-3.92%$4.8B
TVTXTravere Therapeutics Inc.$49.70-1.88%$4.8B
IONSIonis Pharmaceuticals Inc.$28.01-3.61%$4.7B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier